Literature DB >> 28891852

Condyloma Acuminatum, Anal Intraepithelial Neoplasia, and Anal Cancer in the Setting of HIV: Do We Really Understand the Risk?

Edward A Fazendin1, Alexander J Crean, Jessica M Fazendin, Robert J Kucejko, Harkenwar S Gill, Juan L Poggio, David E Stein.   

Abstract

BACKGROUND: The gold standard for surveillance of patients with anal lesions is unclear.
OBJECTIVE: The aim of this study was to stratify patients for risk of progression of disease and to determine appropriate intervals for surveillance of patients with anal disease.
DESIGN: This was a retrospective chart review for patients treated for anal lesions between 2007 and 2014. Only patients with ≥1 year of follow-up from index evaluation, pathology, documented physical examination, and anoscopy findings were included for analysis. SETTINGS: The study was conducted at an urban university hospital. PATIENTS: HIV-positive patients with anal lesions treated with excision and fulguration were included. MAIN OUTCOME MEASURES: Recurrence of anal lesions, progression of disease, and progression to cancer were measured.
RESULTS: Ninety-one patients met inclusion criteria. The mean age was 41.6 years, and mean follow-up was 38.6 months (range, 11.0-106.0 mo). On initial pathology, 8 patients (8.8%) had a diagnosis of condyloma acuminatum without dysplasia, 20 patients (22%) had anal intraepithelial neoplasia I, 32 (35.2%) had anal intraepithelial neoplasia II, and 31 (34.1%) had anal intraepithelial neoplasia III. Sixty-nine patients (75.8%) had repeat procedures. Seven (87.5%) of 8 patients with condyloma and 6 (30%) of 20 patients with anal intraepithelial neoplasia I progressed to high-grade lesions. Five (15.6%) of 32 patients progressed from anal intraepithelial neoplasia II to III, and 2 patients with anal intraepithelial neoplasia III (6.5%) developed squamous cell carcinoma (2.3% for the entire cohort). LIMITATIONS: This was a single institution study. High-resolution anoscopy was not used.
CONCLUSIONS: All of the HIV-positive patients with condyloma or anal intraepithelial neoplasia, regardless of the presence of dysplasia, should be surveyed at equivalent 3-month time intervals, because their risk of progression of disease is high. Video Abstract at http://links.lww.com/DCR/A389.

Entities:  

Mesh:

Year:  2017        PMID: 28891852     DOI: 10.1097/DCR.0000000000000890

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  6 in total

1.  Progression of anal intraepithelial neoplasia in HIV-positive individuals: predisposing factors.

Authors:  T McCutcheon; A T Hawkins; R L Muldoon; M B Hopkins; T M Geiger; M M Ford
Journal:  Tech Coloproctol       Date:  2019-04-23       Impact factor: 3.781

2.  Biomarker P16 predicts progression risk of anal low-grade squamous intraepithelial lesions.

Authors:  Yuxin Liu; Morgan Blakely; Keith Sigel; Tin Htwe Thin; Pei Hui; Michael Donovan; Michael M Gaisa
Journal:  AIDS       Date:  2018-10-23       Impact factor: 4.177

3.  What Is the Risk of Anal Carcinoma in Patients With Anal Intraepithelial Neoplasia III?

Authors:  Grace C Lee; Hiroko Kunitake; Holly Milch; Lieba R Savitt; Caitlin E Stafford; Liliana G Bordeianou; Todd D Francone; Rocco Ricciardi
Journal:  Dis Colon Rectum       Date:  2018-12       Impact factor: 4.585

4.  Prevalence of High-Grade Anal Dysplasia and Anal Cancer in Veterans Living With HIV and CD4/CD8 Ratio as a Marker For Increased Risk: A Regional Retrospective Cohort Study.

Authors:  Cristina B Sanger; Yiwei Xu; Evie Carchman; Elise H Lawson; Charles P Heise; Rob Striker; Corrine I Voils
Journal:  Dis Colon Rectum       Date:  2021-07-01       Impact factor: 4.412

5.  Therapeutic effect of photodynamic therapy combined with imiquimod in the treatment of anal condyloma acuminatum and its effect on immune function.

Authors:  Xianmin Meng; Yongguo Li; Hong Luan; Xiuyan Shi
Journal:  Exp Ther Med       Date:  2018-09-03       Impact factor: 2.447

6.  The Spontaneous Control of HIV Replication is Characterized by Decreased Pathological Changes in the Gut-associated Lymphoid Tissue.

Authors:  Natalia A Taborda; Luis A Correa; Manuel Geronimo Feria; María T Rugeles
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.